Autolus Therapeutics plc Earnings Per Share (Basic)
Autolus Therapeutics plc (AUTL) reported Earnings Per Share (Basic) of -$0.15 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- Autolus Therapeutics plc earnings per share, basic for the quarter ending 2026-06-30 was -$0.15.
- Autolus Therapeutics plc earnings per share, basic for the quarter ending 2026-03-31 was -$0.27.
- Autolus Therapeutics plc earnings per share, basic for the quarter ending 2025-12-31 was -$0.34.
- Autolus Therapeutics plc earnings per share, basic for the quarter ending 2025-09-30 was -$0.30.
- Autolus Therapeutics plc earnings per share, basic for fiscal 2025 was -$1.08.
- Autolus Therapeutics plc earnings per share, basic for fiscal 2024 was -$0.86.
- Autolus Therapeutics plc earnings per share, basic for fiscal 2023 was -$1.20.
- Autolus Therapeutics plc earnings per share, basic for fiscal 2022 was -$1.57.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.15 10-Q · filed 2026-08-11 | -$0.42 10-Q · filed 2026-08-11 | -$0.76 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.27 10-Q · filed 2026-05-14 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$1.09 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$0.82 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.08 10-K · filed 2026-03-27 |
| 2025-09-30 | -$0.30 10-Q · filed 2025-11-12 | -$0.48 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.74 10-Q · filed 2025-11-12 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.18 10-Q · filed 2026-08-11 | -$0.44 10-Q · filed 2026-08-11 | -$0.55 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.86 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$0.26 10-Q · filed 2026-05-14 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.68 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-05-14 |
| 2024-12-31 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$0.63 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$0.86 10-K · filed 2026-03-27 |
| 2024-09-30 | -$0.31 10-Q · filed 2025-11-12 | -$0.53 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$0.77 10-Q · filed 2025-11-12 | -$1.16 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-06-30 | -$0.22 10-Q · filed 2025-08-12 | -$0.43 10-Q · filed 2025-08-12 | -$0.85 derived: net income ÷ weighted average shares · filed 2025-08-12 | -$1.12 derived: net income ÷ weighted average shares · filed 2025-08-12 |
| 2024-03-31 | -$0.24 10-Q · filed 2025-05-08 | -$0.66 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$0.92 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$1.19 derived: net income ÷ weighted average shares · filed 2025-05-08 |
| 2023-12-31 | -$0.44 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$0.71 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$0.97 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$1.20 10-K · filed 2025-03-20 |
| 2023-09-30 | -$0.26 10-Q · filed 2024-11-12 | -$0.53 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$0.75 10-Q · filed 2024-11-12 | -$1.01 derived: net income ÷ weighted average shares · filed 2024-11-12 |
| 2023-06-30 | -$0.26 10-Q · filed 2024-08-08 | -$0.49 10-Q · filed 2024-08-08 | -$0.74 derived: net income ÷ weighted average shares · filed 2024-08-08 | -$1.14 derived: net income ÷ weighted average shares · filed 2024-08-08 |
| 2023-03-31 | -$0.23 10-Q · filed 2024-05-17 | -$0.48 derived: net income ÷ weighted average shares · filed 2024-05-17 | -$0.88 derived: net income ÷ weighted average shares · filed 2024-05-17 | |
| 2022-12-31 | -$0.25 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$0.70 derived: net income ÷ weighted average shares · filed 2024-03-21 | -$1.57 10-K · filed 2024-03-21 | |
| 2022-09-30 | -$0.47 10-K · filed 2024-03-21 | -$1.34 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$0.46 10-K · filed 2024-03-21 | |||
| 2022-03-31 | -$0.41 10-K · filed 2024-03-21 | |||
| 2021-12-31 | -$1.97 10-K · filed 2024-03-21 | |||
| 2020-12-31 | -$2.76 20-F · filed 2023-03-07 | |||
| 2019-12-31 | -$2.88 20-F · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |